We occasionally write about the new innovations we discover and the insights we come up with through our analytical and creative work. For daily digital health updates, we recommend connecting with our CEO, Koen Kas, on LinkedIn. Koen has also written pivotal books in the field, including most recently “Your Guide to Delight”.
Today is DNA day. Actually everyday should be DNA day. Slower than anticipated – and for good reason – the actual genome revolution, part of
This week everybody has seen that post on The Mall. MetaVRse has been working on TheMall for seven years. Launch expected in the fourth quarter of
To me, the health event of 2022 will be the launch of a citizen-centric data platform “We Are”.Soon, we will see the official launch of
We’re often asked by pharma customers to explore how we could accelerate diagnosis and guide patients to the right treatment faster, especially in therapeutic domains
Real World Data & Digital Biomarkers In the summer of 2012 I experienced my first workation. In Piemonte, the north of Italy, in a city
Blockchain for precision medicine The road towards precision medicine, developing medication as targeted as possible, is an extremely complex and lengthy process. We took a
By reviewing recent innovations in prostate cancer I hope to throw some light on what optimal prostate cancer care could and should like. Relevant for professionals, but also patients and their loved ones, so that you can raise your expectations and hopefully play your part in accelerating progress in the field.
The road towards precision medicine is an extremely complex and lengthy process. Patients would benefit from the pure personalised character of the drug. Apart from
While digital health investment rockets on in areas such as telehealth, online pharmacies, weight loss and diabetes, one broadly defined therapeutic area has thus far
Hospitals and pharma companies have traditionally looked at themselves as transactional partners, but that relationship is changing dramatically. Hospitals have improved their leverage as partners,